BRIEF-R1 Therapeutics Announces Launch With An Oversubscribed $77.5 Million Series A Financing

Reuters19:00

BRIEF-R1 <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Launch With An Oversubscribed $77.5 Million Series A Financing

March 17 (Reuters) - DaVita Inc DVA.N:

R1 THERAPEUTICS: EXCLUSIVE GLOBAL LICENSE TO DEVELOP, COMMERCIALIZE AP306 OUTSIDE OF GREATER CHINA FROM ALEBUND PHARMACEUTICALS
R1 THERAPEUTICS ANNOUNCES LAUNCH WITH AN OVERSUBSCRIBED $77.5 MILLION SERIES A FINANCING
R1 THERAPEUTICS: PROCEEDS FROM SERIES A FINANCING TO FUND R1'S GLOBAL DEVELOPMENT PROGRAM OF AP306
R1 THERAPEUTICS: FINANCING WAS CO-LED BY ABINGWORTH, F-PRIME, & DAVITA VENTURE GROUP, WITH PARTICIPATION FROM CURIE.BIO, SYMBIOSIS, & U.S. RENAL CARE

Source text: [ID:]

Further company coverage: DVA.N

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620429856?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620429856","market":"us","top_or_hot":-1,"title":"BRIEF-R1 Therapeutics Announces Launch With An Oversubscribed $77.5 Million Series A Financing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-R1 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Launch With An Oversubscribed $77.5 Million Series A Financing</title></head><body><p><span>March 17 (Reuters)</span><span> - </span>DaVita Inc <span>DVA.N</span>:</p><ul><li><p>R1 THERAPEUTICS: EXCLUSIVE GLOBAL LICENSE TO DEVELOP, COMMERCIALIZE AP306 OUTSIDE OF GREATER CHINA FROM ALEBUND PHARMACEUTICALS</p></li><li><p>R1 THERAPEUTICS ANNOUNCES LAUNCH WITH AN OVERSUBSCRIBED $77.5 MILLION SERIES A FINANCING</p></li><li><p>R1 THERAPEUTICS: PROCEEDS FROM SERIES A FINANCING TO FUND R1'S GLOBAL DEVELOPMENT PROGRAM OF AP306</p></li><li><p>R1 THERAPEUTICS: FINANCING WAS CO-LED BY ABINGWORTH, F-PRIME, &amp; DAVITA VENTURE GROUP, WITH PARTICIPATION FROM CURIE.BIO, SYMBIOSIS, &amp; U.S. RENAL CARE</p></li></ul><p>Source text: [ID:]</p><p>Further company coverage: <span>DVA.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-R1 Therapeutics Announces Launch With An Oversubscribed $77.5 Million Series A Financing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-R1 Therapeutics Announces Launch With An Oversubscribed $77.5 Million Series A Financing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-17 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-R1 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Launch With An Oversubscribed $77.5 Million Series A Financing</title></head><body><p><span>March 17 (Reuters)</span><span> - </span>DaVita Inc <span>DVA.N</span>:</p><ul><li><p>R1 THERAPEUTICS: EXCLUSIVE GLOBAL LICENSE TO DEVELOP, COMMERCIALIZE AP306 OUTSIDE OF GREATER CHINA FROM ALEBUND PHARMACEUTICALS</p></li><li><p>R1 THERAPEUTICS ANNOUNCES LAUNCH WITH AN OVERSUBSCRIBED $77.5 MILLION SERIES A FINANCING</p></li><li><p>R1 THERAPEUTICS: PROCEEDS FROM SERIES A FINANCING TO FUND R1'S GLOBAL DEVELOPMENT PROGRAM OF AP306</p></li><li><p>R1 THERAPEUTICS: FINANCING WAS CO-LED BY ABINGWORTH, F-PRIME, &amp; DAVITA VENTURE GROUP, WITH PARTICIPATION FROM CURIE.BIO, SYMBIOSIS, &amp; U.S. RENAL CARE</p></li></ul><p>Source text: [ID:]</p><p>Further company coverage: <span>DVA.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DVA","symbol_name":"达维塔保健","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nP8N40008G:1","article_id":"2620429856","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620429856","pubTimestamp":1773745201,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-R1 Therapeutics Announces Launch With An Oversubscribed $77.5 Million Series A FinancingMarch 17  - DaVita Inc DVA.N:R1 THERAPEUTICS: EXCLUSIVE GLOBAL LICENSE TO DEVELOP, COMMERCIALIZE AP306 OUTSIDE OF GREATER CHINA FROM ALEBUND PHARMACEUTICALSR1 THERAPEUTICS ANNOUNCES LAUNCH WITH AN OVERSUBSCRIBED $77.5 MILLION SERIES A FINANCINGR1 THERAPEUTICS: PROCEEDS FROM SERIES A FINANCING TO FUND R1'S GLOBAL DEVELOPMENT PROGRAM OF AP306R1 THERAPEUTICS: FINANCING WAS CO-LED BY ABINGWORTH, F-PRIME, & DAVITA VENTURE GROUP, WITH PARTICIPATION FROM CURIE.BIO, SYMBIOSIS, & U.S. RENAL CARESource text: [ID:]Further company coverage: DVA.N ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DVA":"达维塔保健","BK4588":"碎股","BK4559":"巴菲特持仓","BK4196":"保健护理服务","BK4585":"ETF&股票定投概念"},"translate_title":"BRIEF-R1 Therapeutics宣布推出超额认购7750万美元A轮融资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DVA":0.9},"content_text":"BRIEF-R1 Therapeutics Announces Launch With An Oversubscribed $77.5 Million Series A FinancingMarch 17 (Reuters) - DaVita Inc DVA.N:R1 THERAPEUTICS: EXCLUSIVE GLOBAL LICENSE TO DEVELOP, COMMERCIALIZE AP306 OUTSIDE OF GREATER CHINA FROM ALEBUND PHARMACEUTICALSR1 THERAPEUTICS ANNOUNCES LAUNCH WITH AN OVERSUBSCRIBED $77.5 MILLION SERIES A FINANCINGR1 THERAPEUTICS: PROCEEDS FROM SERIES A FINANCING TO FUND R1'S GLOBAL DEVELOPMENT PROGRAM OF AP306R1 THERAPEUTICS: FINANCING WAS CO-LED BY ABINGWORTH, F-PRIME, & DAVITA VENTURE GROUP, WITH PARTICIPATION FROM CURIE.BIO, SYMBIOSIS, & U.S. RENAL CARESource text: [ID:]Further company coverage: DVA.N ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620429856","isCrawlerRequest":true}